Introduction
Adrenomedullin (ADM) is a secreted multifunctional 52-amino-acid peptide hormone involved in numerous physiological and pathological processes including regulation of vasomotor tone, cell differentiation, growth regulation and angiogenesis, and its expression has been demonstrated in several tumors and tumor cell lines (Belloni et al., 2001) . The exact role played by ADM in tumorigenesis, however, is yet to be established.
Angiogenesis is fundamental for tumor progression in the form of growth, invasion and metastasis, and is regulated by several growth factors for endothelial cells secreted by both tumor and host inflammatory cells, and mobilized from extracellular matrix strores by proteases secreted by tumor cells . Recently, it has been demonstrated by several groups that ADM is protumorigenic by stimulating carcinoma cell growth and angiogenesis directly (Fujita et al., 2002; Hague et al., 2000; Martinez et al., 2002; Oehler et al., 2002; Ishikawa et al., 2003) . As such, ADM is identified as a novel target for antiangiogenic therapy.
We have previously investigated about the antiangiogenic activity of several chemotherapeutic agents, such as vinblastine (VBL), purine analogs, docetaxel and paclitaxel (Presta et al., 1999; 2002; Vacca et al., 1999; 2002) . On this basis, in this study we addressed the possibility that VBL may act as an angiostatic molecule in the angiogenic response induced by ADM in two assays, such as Matrigel tube formation in vitro and angiogenesis in the chick embryo chorioallantoic membrane (CAM) in vivo.
After seeding on Matrigel, endothelial cells remained spherical and isolated in the presence of serum-free medium, with small cellular nests and short tubes rarely observed. By contrast, ADM (10 À8 m) and FGF-2 (100 ng/ml) caused a morphogenetic effect. In fact, endothelial cells spread and aligned with each other to form branching anastomosing tubes with multicentric junctions that gave rise to a meshwork of capillary-like structures in 18 h. When ADM was administered in the presence of VBL (10 À12 m), the capillary-like tubes were interrupted, most cells were spherical, either isolated or aggregated in small clumps. An overlapping inhibitory effect was obtained after administration of VBL alone (10 À12 m). As concerns the results of the image-analysis evaluations, ADM did not alter dimensional (area % covered by the endothelial cells and the total length of the cell network per field) and topological (the number of mesh and the number of branching points per field) parameters of the capillary-like network at 6 h, but significantly increased them at 18 h of exposure ( Figure 1 ). All these parameters were downloaded when ADM was administered in the presence of VBL ( Figure 1 ). As expected, FGF-2 alone and VBL alone markedly increased and, respectively, inhibited these parameters ( Figure 1) .
As concerns the results of the in vivo experiments, macroscopic observations of the CAM at day 12 showed that the sponges adsorbed with ADM were surrounded by allantoic vessels developing radially towards the implant in a 'spoked-wheel' pattern ( Figure 2a) . No vascular reaction was detectable around the sponges treated with PBS only. Microscopically, a highly vascularized tissue was observed among the trabeculae of the ADM-treated sponges consisting of newly formed blood vessels within an abundant network of collagen fibers (Figure 2b) . No blood vessels were recognizable among the sponges treated with PBS only. In agreement with the macroscopic and microscopic observations, morphometric evaluations demonstrated that microvessel density was higher within the sponges treated with ADM than in those treated with vehicle alone and comparable to that of the sponges treated with FGF-2 (Table 1 ). When ADM was tested in combination with its antagonists CGRP 8-37 and ADM 22-52, both administered at 50 pm/embryo, or VBL at three different concentrations (0.5, 0.75 and 1 pmol/l), a significantly reduction of its angiogenic activity was appreciable macroscopically, microscopically and morphometrically (Figure 2c, d and Table 1 ).
Here we show for the first time that VBL inhibits angiogenesis by ADM in two assays, such as endothelial morphogenesis in vitro and angiogenesis in the chick embryo CAM in vivo. As concerns the mechanism of action of VBL, it has been shown that VBL uptake into the microvascular endothelial cells is already operative at very low doses in the extacellular milieu (El Hafny et al., 1997) . The doses we used caused nonspecific cytotoxicity: 1 pmol/l caused endothelial cell cytoplasmic vacuolization and swelling and loss of elongated cell shape. In the CAM assay, 1 pmol/l gave vascular degeneration and cytoplasmic fragmentation of endothelial cells 4 days afterwards. A dose of 1 pmol/l is equivalent to a dose of 16 mg in a 70 kg adult, which corresponds to a much lower dose of the drug than that used in current anticancer treatments. By contrast, doses of 2 pmol/l or greater were rapidly cytotoxic both in vitro and in vivo. Additional proof of the absence of cytotoxicity in our model was provided by the complete reversal of both in vitro and in vivo inhibition when VBL was removed.
ADM role in the vasculature has been recently reviewed (Nikitenko et al., 2002) . Endothelial cells and vascular smooth muscle cells both actively secrete ADM and express its receptors (Minamino et al., 2000) . ADM is a potent endogenous vasodilator synthesized and secreted by adrenal gland, lung and kidney. Transgenic and gene knockout models further emphasize that ADM is crucial to vascular morphogenesis and function (Caron and Smithies, 2001; Shindo et al., 2001) . ADM knockout have a lethal homozygous phenotype with abnormal vascular development (Caron and Smithies, Matrigel tube formation assay. Unpolymerized Matrigel (Becton Dickinson, Mountain View, CA, USA) was thawed on ice overnight and spread evenly over each well (50 ml) of a 24 well plate. The plates were incubated for 30 min at 371C to allow the Matrigel to gel. HUVECs (2.5 Â 10 4 cells/cm 2 well) were seeded into each well supplemented with DMEM alone or with: ADM (10 À8 m); FGF-2 (100 ng/ml); VBL(10 À12 m); ADM (10 À8 m) plus VBL (10 À12 m). Cultures were incubated for 6-18 h at 371C. At the end of incubation period, from each well, five fields of view were photographed (four quadrants and the center) at a primary magnification of Â 5. Phase contrast images were captured using a digital camera (DC200, Leica Imaging Systems Ltd, Cambridge, UK) attached to a Laborlux S microscope (Leitz) and saved as TIFF files. Image analysis was carried out using QWin image analysis software (Leica Imaging Systems Ltd, Cambridge, UK). Briefly, after contour enhancement and thresholding, a geometric filter was applied to remove profiles of very small size or exhibiting a circular shape, allowing the identification of the network formed by the cells. The percent area covered by the cells (area %) was then assessed. After skeletonization of the binary image, the total length per field (length) of the cell network was also evaluated. The binary image was further processed to extract the regions of the field of view delimited by cells (i.e. the mesh of the network) and the points where branching occurred. The number of mesh per field (mesh) and the number of branching points per field (branching) were then estimated and used to characterize the topological structure of the endothelial cell organization. Values observed in the treated cultures were statistically compared to those obtained in the correspondent control cultures by Student's t-test for paired data. (a, b) treatment-induced changes in the dimensional (a) and topological (b) parameters of the network formed by endothelial cells seeded in Matrigel after 18 h of culture. ADM significantly increases dimensional (area % covered by the endothelial cells and the total length of the cell network per field) and topological (the number of mesh and the number of branching points per field) parameters of the capillary-like network. All these parameters are downloaded when ADM is administered in the presence of VBL. As expected, FGF-2 alone and VBL alone markedly increase and, respectively, inhibit these parameters Adrenomedullin and antiangiogenesis D Ribatti et al 2001; Shindo et al., 2001 ) and strong expression of ADM has been found in the developing murine vasculature (Caron and Smithies, 2001). Zhao et al. (1998) have demonstrated that ADM is an endothelial cell growth factor and is angiogenic in the chick CAM assay.
ADM has also been implicated in tumor cell biology. Expression of ADM was demonstrated in several tumors including small-cell and nonsmall-cell lung carcinomas, astrocytomas and glioblastomas, pheochromocytomas, aldosteronomas, nonfunctioning adrenal adenomas, cortisol-secreting adenomas and adrenal carcinomas, ectopic ACTH-secreting and human prostate adenocarcinomas (Belloni et al., 2001) . In addition, ADM expression and ADM receptors have been detected in several tumor cell lines derived from lung large-and small-cell squamous and bronchioalveolar carcinomas, breast carcinomas, colon adenocarcinomas, glioblastomas, neuroblastomas, ovarian adenocarcinomas, prostate carcinomas, adrenocortical carcinomas, chondrosarcomas, monocytic leukemia and skin melanomas (Belloni et al., 2001) .
In endometrial carcinoma xenografts, the ADM is protumorigenic by stimulating either angiogenesis alone or by stimulating angiogenesis and carcinoma cell growth directly (Oehler et al., 2002) . Human breast cancer cell lines overexpressing ADM displayed an increased angiogenic potential both in vitro and in vivo (Martinez et al., 2002) . ADM and vascular endothelial growth factor (VEGF) are the most widely expressed angiogenic factors in uterine leiomyomas (Hague et al., 2000) , while ADM expressed in human renal cell carcinoma is induced by hypoxia and coexpression of ADM and VEGF, indicating that ADM may increase blood flow by vasodilation in the tumor vessels induced by VEGF and subsequently promote tumor growth (Fujita et al., 2002) . Ishikawa et al. (2003) demonstrated that ADM antagonist significantly reduced the in vivo growth of a pancreatic cancer cell line indirectly, by suppressing the formation of large functional blood vessels in the tumor tissues, leading to depletion of nutrient and oxygen supply.
Inhibitors of angiogenesis block any of the several steps in the angiogenic cascade, including proliferation and attachment of endothelial cells to the extracellular matrix proteins, migration and invasion through the matrix, which is required for the capillary sprouting, morphogenesis, differentiation and stabilization (Kerbel and Folkman, 2002) . It has been demonstrated that cytoskeleton-toxic chemotherapeuticals, such as VBL, at very low doses display antiangiogenic activity without nonspecific cytotoxic or necrotic damage . As concerns the effects of VBL on tumor proliferation, Klement et al. (2000) administered VBL at one-tenth to one-twentieth of the maximum tolerated doses in xenografts of neuroblastoma cell lines. They observed a significant xenograft regression, diminished tumor perfusion and direct inhibition of angiogenesis. At present, further studies are ongoing in our lab to demonstrate the antitumor effect of VBL on xenografts of human cancer cell lines overexpressing ADM. Figure 2 In vivo CAM assay. Fertilized White Leghorn chicken eggs (30/group) were incubated under constant humidity at 371C. On incubation day 3, a square window was opened in the shell to detach the developing CAM after removal of 2-3 ml of albumen. CAMs were treated at day 8 with 100 pm of human ADM dissolved in 2 ml PBS and adsorbed on 1 mm 3 sterilized gelatin sponges (Gelfoam, Upjohn Company, Kalamazoo, USA). In some experiments, ADM was mixed with 50 pm/embryo of its antagonists, human calcitonin gene-related peptide (CGRP) 8-37, human ADM 22-52 (Peptide Institute Inc., Osaka, Japan) or VBL at three different concentrations (0.5, 0.75, 1 pmol/l) before implantation. Sponges containing vehicle alone (PBS) were used as negative controls, while sponges containing 1.0 mg/embryo of recombinant human FGF-2 (R&D Systems, Abingdon, UK) were used as positive controls. All procedures were performed under sterile conditions. CAMs were examined daily until day 12 and photographed in ovo with a Zeiss SR equipped with the MC63 Camera System (Zeiss, Oberkochen, Germany). In some experiments, blood vessels entering the sponge within the focal plane of the CAM were counted by two observers in a double-blind fashion at Â 50 magnification. Then CAMs were fixed in ovo in Bouin's fluid, dehydrated in graded ethanols, embedded in paraffin, serially sectioned at 7 mm, according to a plane perpendicular to their free surface and stained with a 0.5% acqueous solution of toluidine blue (Merck, Darmstadt, Germany). The angiogenic response was evaluated as microvessel density in the CAM area under the implant. The area occupied by microvessels was estimated by using a morphometric method of 'point counting' (Ribatti et al., 1997) with slight modifications. Briefly, every third section with 60 serial slides for each specimen was analysed simultaneously by two investigators by a 144-intersection point-square reticulum of 0.125 mm 2 inserted in the eyepiece of a double-head Leitz Dialux 20 photomicroscope (Leitz, Wetzlar, Germany). Only transversally sectioned microvessels (diameter ranging from 3 to 10 mm) were counted and calculated as the mean71s.d. per section, per specimen and groups of specimens. The microvessel area was indicated by the final mean number of the occupied intersection points, expressed again as a percentage of the total number of intersection points. The statistical significance of the differences between the counts in the experimental and control CAMs was determined by Student's t-test for unpaired data. Macroscopic observations at day 12 show that the sponges adsorbed with human ADM were surrounded by allantoic vessels developing radially towards the implant in a 'spoked-wheel' pattern (a). Microscopically, a highly vascularized tissue is observed among the trabeculae of the ADM-treated sponge, consisting of newly formed blood vessels within an abundant network of collagen fibers (b). When ADM is administered in combination with VBL, a significant reduction of angiogenic response is appreciable at macroscopic level (c), while no blood vessels are detectable inside the sponge (d)
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Overall, these observations implicate ADM as a promoter of tumor growth and a possible target for anticancer strategies, such as the use of VBL at very low, nontoxic doses. Nevertheless, the antiangiogenic activity of low-dose VBL deserves further investigation, alone or together with other antiangiogenic agents for the treatment of tumors characterized by enhanced angiogenesis. 
